Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. The lack of head-to-head trials complicates treatment prioritization, ...
The last time I spoke about Madrigal Pharmaceuticals (MDGL), it was with respect to a Seeking Alpha article entitled "Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term." ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results